Tissue Protective Peptide

ARA-290

Cibinetide • Helix B Surface Peptide • EPO-Derived Repair Signal

ARA-290 is an 11 amino acid peptide derived from the tissue protective domain of erythropoietin. It is researched for small fiber neuropathy, nerve regeneration, inflammation control, metabolic improvement, and tissue protection without increasing red blood cell production, hematocrit, blood viscosity, or blood pressure.

Nerve Repair Anti-Inflammatory Physical Function Human Trial Data

Protocol Snapshot

ARA-290 Quick Reference

Verified Vendors

ARA-290

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Trial Dose

4mg

Once daily by subcutaneous injection in published Phase 2 studies.

Treatment Course

28 days

Treatment stopped after day 28; longer continuous use was not established.

Community Titration

2 → 4mg

Week 1 at 2mg daily, then 4mg daily for weeks 2–4.

Route

SubQ

Review the full protocol details below.

Peptide Grade

GradeB

Human trials give ARA-290 a credible signal for neuropathic symptoms and tissue-protective signaling without stimulating red blood cells, but small studies, investigational status, and uncertain community dosing keep it below the top tier.

Research Community Safety

No increase in red blood cell count, hematocrit, blood pressure, clotting risk, or anti-drug antibodies in trials.

Foundation

Research context, mechanisms, and practical use cases

What is ARA-290?

ARA-290 is a synthetic 11 amino acid peptide derived from the tissue protective domain of erythropoietin (EPO). Its sequence is Pyr-Glu-Glu-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser. It is also known as cibinetide and helix B surface peptide (HBSP). Its molecular weight is 1257 Da.

If you have heard of EPO, you know it as the hormone your kidneys produce to stimulate red blood cell production. Athletes have abused it for decades to increase oxygen carrying capacity. But EPO also has powerful tissue protective and anti-inflammatory effects that are completely separate from its blood building activity.

The problem is that when you give someone EPO for tissue protection, you also get all the dangerous blood effects: elevated hematocrit, increased clotting risk, hypertension, and cardiovascular complications.

Researchers identified that EPO's tissue protective effects are mediated by a different receptor than its blood building effects. They mapped the specific region of the EPO molecule responsible for tissue protection, the helix B surface domain, and engineered ARA-290 to mimic just that region.

Why ARA-290 Matters

The result is a peptide that activates tissue repair and calms inflammation without touching red blood cell production, hematocrit, blood viscosity, or blood pressure.

ARA-290 has been studied in multiple Phase 2 clinical trials across sarcoidosis-associated small fiber neuropathy and diabetic neuropathy, giving it a more substantial human evidence base than many experimental repair peptides.

ARA-290 Benefits

The benefits of ARA-290 are supported by multiple human clinical trials, which puts it ahead of many peptides in the healing and recovery category where evidence is often limited to animal models.

Small Fiber Neuropathy Relief

The strongest clinical evidence comes from neuropathy studies. In sarcoidosis patients, ARA-290 produced a 28% reduction in Small Fiber Neuropathy Screening List scores compared to 9% for placebo.

Nerve Fiber Regeneration

Corneal confocal microscopy confirmed increased nerve fiber area and density after 28 days. GAP-43 positive regenerating nerve fibers increased significantly in the 4mg dose group.

Metabolic Improvement

In type 2 diabetic patients, ARA-290 improved HbA1c by 0.21%, improved cholesterol to HDL ratio, increased HDL, and decreased triglycerides.

Pain & Function

ARA-290 improved pain and physical functioning dimensions of quality of life assessments. The 6 minute walk test improved by 18.7 meters versus a 15.1 meter decline in placebo.

Anti-Inflammatory Effects

ARA-290 reduces pro-inflammatory cytokines including TNF-alpha, IL-1 beta, and IL-6 through NF-kB inhibition without broad immunosuppression.

Organ Protection

Preclinical research shows protection in kidney ischemia reperfusion injury, age-related cardiac inflammation, pancreatic islet transplantation, and ischemic stroke models.

Bone Health

A 2021 study showed cibinetide inhibited osteoclastogenesis and increased cortical and trabecular bone mineral density after one month in mice.

Clinically Distinct

ARA-290 does not just mask neuropathic symptoms. It has evidence suggesting actual structural nerve regrowth.

Why This Is Different

Most neuropathy treatments only mask pain. ARA-290 has demonstrated symptom relief plus measurable nerve fiber regeneration in controlled human trials.

Protocol Planning

Dosing, cycling, and preparation

ARA-290 Protocol

Published Phase 2 Protocol

Dose

4mg once daily

Route

Subcutaneous injection

Titration

None in the published daily SubQ regimen

Course

28 consecutive days, then treatment stopped

After Day 28

Participants were observed off treatment; continuous use beyond 28 days has not been established in published trials

Titration Approach — Community Practice

Week 1

2mg daily to assess tolerance

Weeks 2–4

4mg daily as the full therapeutic dose

Route

Subcutaneous injection

Evidence Note

This stepped schedule reflects community practice, not the published Phase 2 trial design

ARA-290 Reconstitution

Published trials used a prepared study-drug formulation in sodium-phosphate buffer with sucrose and mannitol. For lyophilized supplier vials, sterile PBS is generally preferred when the supplier confirms it is compatible and appropriate for the intended research use. BAC water may be acceptable when the supplier specifically confirms compatibility. Do not substitute generic laboratory-grade PBS.

10mg Vial Calculator Example

Vial Size

10mg

Preferred Diluent

1mL sterile PBS when the supplier confirms PBS compatibility

BAC Water

May be used when the supplier confirms BAC-water compatibility

Concentration

10mg/mL

4mg Dose

0.4mL, or 40 units on a U-100 syringe

Handling

Swirl gently if needed. Do not shake.

Reconstitution Calculator

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Users with diabetic, autoimmune, or idiopathic neuropathy commonly report reduced burning and tingling within the first 1–2 weeks.
Some users report noticeable improvement within hours of dosing, although sustained benefit is usually described as requiring continued daily use.
Functional gains are often described as gradual, including improved walking tolerance, reduced pain interference, and better day-to-day mobility.

Negative Reports

A mild sting or irritation at the injection site is one of the more common practical complaints.
Some users report little or no noticeable improvement, particularly with longstanding or severe neuropathy.
Individual response appears to vary with the cause, severity, and duration of the underlying neuropathy.

Stacking & Synergy

Potential ARA-290 pairings and tracking context

ARA-290 Stacking & Synergy

ARA-290 + BPC-157 and TB-500

No published data exists on this combination. ARA-290 works through the innate repair receptor, BPC-157 primarily through VEGFR2 upregulation and angiogenesis, and TB-500 through actin upregulation and cell migration.

Wolverine Stack Use Case

For someone with both nerve damage and musculoskeletal injury, ARA-290 alongside BPC-157 plus TB-500 addresses different tissue types through different pathways.

ARA-290 + KPV

Theoretical but logical. KPV supports inflammatory control while ARA-290 supports nerve repair and tissue-protective signaling. No published studies have tested the combination.

ARA-290 + Cartalax

More speculative. Cartalax is generally discussed around cartilage and connective tissue bioregulation, while ARA-290 is more focused on nerve repair and inflammation. No combination data exists.

Stacking Principle

The strongest stacking rationale is not overlap. It is tissue targeting. ARA-290 is most interesting for nerve injury and neuroinflammation, while BPC-157, TB-500, KPV, and Cartalax are generally aimed at different parts of the repair and inflammation cascade.

Free with login

Track in Journal

Track ARA-290 with the markers that matter most for this compound: dose, cycle day, neuropathy symptoms, pain/function changes, injection-site response, and kidney-function notes.

Dose, route, timing, and cycle day.
Neuropathy symptoms, burning, tingling, and sensory changes.
Pain interference, walking tolerance, function, and side effects.

Start Tracking

Safety Notes

Side effects, contraindications, and precautions

ARA-290 Side Effects

ARA-290 has demonstrated a favorable safety profile across published clinical trials. Reported adverse events were generally mild and occurred at rates similar to placebo.

The main safety signal requiring caution is kidney function. One participant with pre-existing borderline renal insufficiency experienced worsening renal function, although causality was not established.

Common or Mild Reports

Mild headache.
Injection-site sting, redness, or irritation.
Mild nausea or digestive discomfort.
Occasional dizziness or fatigue.

Not Observed in Trials

No increase in red blood cell count or hematocrit.
No increase in blood pressure or clotting risk.
No polycythemia or cardiovascular adverse-event signal.
No pure red cell aplasia or anti-drug antibodies.

Trial Safety Summary

The Heij 2012 pilot reported no adverse events in the ARA-290 group. The Dahan 2013 trial reported one moderate adverse event in the ARA-290 group versus three in placebo. The Brines 2015 trial reported 54 mild, nine moderate, and one severe adverse event in the ARA-290 group versus 61 mild and five moderate in placebo. No serious adverse events were attributed to ARA-290 in any trial.

ARA-290 Contraindications and Precautions

ARA-290 has received FDA Orphan Drug and Fast Track designations for sarcoidosis-associated small fiber neuropathy, but it is not FDA approved for general clinical use.

Use Caution With

Active cancer or tumors. There are growth factor concerns with regenerative compounds, though the IRR pathway is distinct from classical tumor growth pathways and ARA-290 does not increase VEGF.
Pre-existing kidney impairment. One clinical trial participant with borderline renal insufficiency showed worsening, so kidney function should be monitored.
Pregnancy and breastfeeding, because no safety data exists in these populations.
Severe liver disease, because data is limited.
Known hypersensitivity to peptide products.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

We consider ARA-290 a specialist peptide that delivers when standard options fall short. It excels at reducing nerve pain, calming chronic inflammation, and supporting microvascular repair. Users dealing with neuropathy, long COVID, or persistent inflammatory conditions often report meaningful relief.

It’s not a daily foundational peptide for everyone, but in the right context it becomes a standout. We recommend targeted cycles rather than indefinite use. Strong niche tool with real-world utility for those who need it.